Biohaven Licenses Kv7 Platform to SK Biopharmaceuticals for $400M Upfront Plus Milestones and Royalties
BHVN has more than doubled off its 52-week low of $7.48.
Summary
Biohaven signed a global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform and lead candidate opakalim, securing $400M upfront, up to $150M in milestones, and tiered royalties. SKBP also assumes up to $245M in Knopp obligations. Closing is pending HSR clearance.
Key Events · M&A and Partnerships · BHVN
-
Global License for Kv7 Platform
Biohaven grants SK Biopharmaceuticals an exclusive, worldwide, royalty-bearing license to its Kv7 ion channel platform, led by opakalim (BHV-7000), a Phase 2/3 candidate for focal epilepsy.
-
$400M Upfront, Non-Dilutive
SKBP pays $400 million in cash — $350 million at closing and $50 million one year later — plus up to $150 million in development and regulatory milestones.
-
Tiered Royalties
Biohaven earns tiered royalties of mid-teens to low twenties on U.S. net sales of opakalim and mid-single-digit royalties on ex-U.S. net sales.
-
Knopp Obligations Assumed
SKBP assumes up to $245 million in Knopp milestone obligations ($185M tied to U.S./EU approval of opakalim, $60M for up to three other Kv7 products) plus a mid-single-digit worldwide royalty to Knopp.
Analysis · BHVN · Life Sciences
Biohaven is monetizing its lead epilepsy asset, opakalim, through a global license to SK Biopharmaceuticals rather than building its own commercial infrastructure. The deal brings $400 million in near-term non-dilutive cash — $350 million at closing and $50 million in 2027 — plus up to $150 million in development and regulatory milestones and tiered royalties ranging from mid-teens to low twenties on U.S. net sales. SKBP also assumes up to $245 million in Knopp milestone obligations and a mid-single-digit worldwide royalty to Knopp, removing those liabilities from Biohaven's balance sheet. The transaction is signed but not closed, pending HSR antitrust clearance. For a company with a $2.17 billion market cap that has been funding itself through ATM offerings, this is a transformative capital event that extends runway without dilution while preserving long-term upside through royalties.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 43.5% of the 1024 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHVN was trading at $15.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $7.48 to $18.57. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.